Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer. 2014 Oct 1;120(19):3058-65. doi: 10.1002/cncr.28843. Epub 2014 Jun 10.
The health and economic burden from liver disease in the United States is substantial and rising. The objective of this study was to characterize temporal trends in mortality from chronic liver disease and liver cancer and the incidence of associated risk factors using population-based data over the past 30 years.
Population-based mortality data were obtained from the National Vital Statistics System, and population estimates were derived from the national census for US adults (aged >45 years). Crude death rates (CDRs), age-adjusted death rates (ADRs), and average annual percentage change (AAPC) statistics were calculated.
In total, 690,414 deaths (1.1%) were attributable to chronic liver disease, whereas 331,393 deaths (0.5%) were attributable to liver cancer between 1981 and 2010. The incidence of liver cancer was estimated at 7.1 cases per 100,000 population. Mortality rates from chronic liver disease and liver cancer increased substantially over the past 3 decades, with ADRs of 23.7 and 16.6 per 100,000 population in 2010, respectively. The AAPC from 2006 to 2010 demonstrated an increased ADR for chronic liver disease (AAPC, 1.5%; 95% confidence interval, 0.3%-2.8%) and liver cancer (AAPC, 2.6%; 95% confidence interval, 2.4%-2.7%).
A comprehensive approach that involves primary and secondary prevention, increased access to treatment, and more funding for liver-related research is needed to address the high death rates associated with chronic liver disease and liver cancer in the United States.
美国的肝病给民众健康和经济带来了沉重负担,且这一负担还在不断加重。本研究旨在利用过去 30 年的人口数据,描述慢性肝病和肝癌死亡率的时间变化趋势,以及相关危险因素的发病情况。
我们从国家生命统计系统获取人口死亡率数据,并从美国成年人(年龄>45 岁)的全国人口普查中得出人口估计值。我们计算了粗死亡率(CDR)、年龄调整死亡率(ADR)和平均年变化百分比(AAPC)。
1981 年至 2010 年期间,共有 690414 人(1.1%)的死亡归因于慢性肝病,331393 人(0.5%)的死亡归因于肝癌。肝癌的发病率估计为每 10 万人中有 7.1 例。过去 30 年来,慢性肝病和肝癌的死亡率大幅上升,2010 年的 ADR 分别为 23.7 和 16.6/10 万人。2006 年至 2010 年的 AAPC 显示,慢性肝病的 ADR 有所增加(AAPC,1.5%;95%置信区间,0.3%-2.8%),肝癌的 ADR 也有所增加(AAPC,2.6%;95%置信区间,2.4%-2.7%)。
需要采取综合方法,包括初级和二级预防、增加治疗机会以及为肝脏相关研究提供更多资金,以解决美国慢性肝病和肝癌死亡率高的问题。